Journal of Neurotrauma
October 19, 2026
Hoda K AbouEich, Ali Izadi, Jonathan Lifshitz et al.
There are currently no available effective pharmacological therapies for treating chronic cognitive deficits after traumatic brain injury (TBI). Psychoplastogens, including atypical psychedelics, classical serotonergic psychedelics, and neuroplastogens, are a class of small molecule drugs that can enhance neuroplasticity by inducing rapid and sustained effects on neuronal architecture and...
Journal of Happytalism and Fundamental Peace
October 18, 2026
Luis Miguel Gallardo
Background Psychedelic medicine is approaching regulatory approval, and suggestion alone can now occasion mystical-type experiences in the laboratory. Yet the field still names altered states after their triggers, and nobody can yet show whether the state itself, rather than its context, is what heals. Objective This review reads the evidence presented at the 2026 Annual Conference of the...
Zenodo (CERN European Organization for Nuclear Research)
October 16, 2026
Francisco Castellanos-Fernández, Francina Solé-Mauri
preprint
Background: Community-based ayahuasca use has spread across Europe, often accompanied by public concern about intensive or escalating involvement. Yet who takes part, what brings them, and how long they stay are poorly documented. Describing these patterns is a prerequisite for proportionate harm reduction, benefit enhancement, and policy. Aims: To describe the demographics, motivations, and...
Zenodo (CERN European Organization for Nuclear Research)
October 14, 2026
Cacho Ernesto
preprint
As psilocybin-assisted therapy becomes increasingly standardized in measuring short-term clinical outcomes, the processes that follow the psychedelic experience remain far less defined. This paper examines integration, aftercare, and long-term follow-up from clinical trials to real-world implementation in Oregon and Colorado, identifying critical gaps and opportunities to better understand,...
Advances in Therapy
October 14, 2026
Ahmed I Anwar, Abdul-Rahman A Hegazi, M Farris Sawaya et al.
Substance use disorders (SUDs) are a major global health burden, and psychedelic-assisted therapies are now gaining scientific interest, with ibogaine being considered as a candidate for anti-addictive effects across multiple substance classes. Ibogaine is a multi-target indole alkaloid acting on opioid, glutamatergic, serotonergic, and sigma systems with potential to rapidly reduce withdrawal...
Art Therapy
October 13, 2026
Uzma Shafi
The ‘Psychedelic Renaissance’ has catalyzed clinical investigation into plant-based therapeutics rooted in indigenous healing traditions, yet as these medicines migrate into Western clinical and commercial frameworks, an epistemological severance occurs: the plant is retained while its relational and artistic contexts are stripped away. Employing a decolonial conceptual methodology, this paper...
Roczniki Psychologiczne
October 13, 2026
Patrycja Bartkiewicz, Wojciech Baran, Ewelina Lachowska
An increasing number of studies have examined the effects of psychedelics on mental wellbeing and their potential use as adjunctive therapy for depressive and anxiety disorders. In this review, we compiled research from the past ten years that focused specifically on the impact of psychedelic use on personality traits. A systematic search was conducted across the databases Web of Science,...
Lviv University Herald Series Psychological sciences
October 12, 2026
Ruslan Hanushchak, Игорь Прись
У статті здійснено ретроспективний огляд розвитку психоделічної терапії та проаналізовано сучасний стан досліджень її ефективності у лікуванні психічних розладів. Простежено еволюцію використання психоделічних речовин – від традиційних духовних і лікувальних практик корінних народів через ранні клінічні дослідження середини ХХ століття до сучасного етапу, так званого «психоделічного ренесансу»....
JORMA International Journal of Health and Social Sciences
October 12, 2026
Michael Sersch
Current interest in the effectiveness of psychedelic-assisted recovery from trauma and other mental health conditions has been increasing. The Native American Church’s (NAC) use of the psychoactive plant peyote for over 100 years within sacred ritual has been a unique approach to religious expression and individual as well as collective healing, especially when addressing cultural trauma as...
Frontiers in Public Health
October 9, 2026
Cecile Giovannetti, Anja Loizaga-Velder, Brian Rush et al.
Background Indigenous peoples experience substantial mental health and substance use disparities while remaining underserved by conventional healthcare systems. Despite growing evidence for psychedelic-assisted therapies, Indigenous knowledge systems and Indigenous-led models of psychedelic care remain underrepresented. This paper describes the establishment and implementation of the Yaqui...